{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T09:37:49Z","timestamp":1793525869357,"version":"4.5.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,2]],"date-time":"2022-11-02T00:00:00Z","timestamp":1667347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,2]],"date-time":"2022-11-02T00:00:00Z","timestamp":1667347200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"National Institute on Aging,United States","award":["R00 AG057797"],"award-info":[{"award-number":["R00 AG057797"]}]},{"name":"Warren Alpert Distinguished Scholars Award","award":["20192684"],"award-info":[{"award-number":["20192684"]}]},{"name":"National Institutes of Health,United States","award":["1R01AG066088-01"],"award-info":[{"award-number":["1R01AG066088-01"]}]},{"name":"National Institutes of Health,United States","award":["1R01AG066088-01"],"award-info":[{"award-number":["1R01AG066088-01"]}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1P30AG062429-01"],"award-info":[{"award-number":["1P30AG062429-01"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1P30AG062429-01"],"award-info":[{"award-number":["1P30AG062429-01"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1P30AG062429-01"],"award-info":[{"award-number":["1P30AG062429-01"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1P30AG062429-01"],"award-info":[{"award-number":["1P30AG062429-01"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Studies have reported higher plasma matrix metalloproteinase-9 (MMP-9) levels in mild cognitive impairment (MCI) and Alzheimer\u2019s disease (AD). Despite evidence that MMP-9 activity and its influence on AD pathophysiology may be modulated by sex hormones, sex differences in the association between MMP-9 and AD biomarkers and cognition have not been explored.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Our sample included 238 amyloid-\u03b2 (A\u03b2)-positive participants with MCI or AD dementia from the Alzheimer\u2019s Disease Neuroimaging Initiative (37.4% women, 74.6 \u00b1 7.3 years). We used linear regression models to examine whether sex modified free and total plasma MMP-9 associations with CSF t-tau, p-tau181, and A\u03b2<jats:sub>42<\/jats:sub>. We used linear mixed effects models to examine whether sex modified total and free plasma MMP-9 associations with cognition, using longitudinal Mini-Mental Status Examination (MMSE) and Alzheimer\u2019s Disease Assessment Scale-Cognitive Subscale (ADAS-cog) data.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Total and free MMP-9 levels did not differ by sex, but AD dementia patients had higher total MMP-9 levels than participants with MCI (<jats:italic>\u03b2<\/jats:italic> = 0.06 [\u22120.11 to \u22120.01], <jats:italic>p<\/jats:italic> = 0.031). Sex modified the association of CSF t-tau with total (<jats:italic>\u03b2<\/jats:italic> = 128.68 [55.37 to 201.99], <jats:italic>p<\/jats:italic> &lt; 0.001) and free MMP-9 (<jats:italic>\u03b2<\/jats:italic> = 98.61 [33.61 to 163.62], <jats:italic>p<\/jats:italic> = 0.003), whereby higher total and free MMP-9 correlated with higher CSF t-tau in women and lower CSF t-tau in men. Higher free MMP-9 correlated with lower CSF p-tau181 among men (<jats:italic>\u03b2<\/jats:italic> = \u221214.98 [\u221227.37 to \u22122.58], <jats:italic>p<\/jats:italic> = 0.018), but not women. In participants with MCI, higher free MMP-9 levels were associated with higher CSF A\u03b2<jats:sub>42<\/jats:sub> among men (<jats:italic>\u03b2<\/jats:italic> = 26.88 [4.03 to 49.73], <jats:italic>p<\/jats:italic> = 0.022) but not women. In the overall sample, higher free and total MMP-9 at baseline predicted worsening MMSE scores in women (<jats:italic>\u03b2<\/jats:italic> = \u22122.10 [\u22123.97 to \u22120.27], <jats:italic>p<\/jats:italic> = 0.027 and <jats:italic>\u03b2<\/jats:italic> = \u22122.24 [\u22124.32 to \u22120.18], <jats:italic>p<\/jats:italic> = 0.035) but not men. Higher free MMP-9 correlated with worse ADAS-cog scores (<jats:italic>\u03b2<\/jats:italic> = 12.34 [3.02 to 21.65], <jats:italic>p<\/jats:italic> = 0.011) in women (<jats:italic>\u03b2<\/jats:italic> = 12.34 [3.02 to 21.65], <jats:italic>p<\/jats:italic> = 0.011) but not men with AD dementia cross-sectionally but correlated with worsening ADAS-cog scores longitudinally only in men (<jats:italic>\u03b2<\/jats:italic> = 8.98 [0.27 to 17.68], <jats:italic>p<\/jats:italic> = 0.042).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>MMP-9 may have more detrimental effects on AD-related pathological and cognitive changes in women. If replicated, our findings could help uncover potential mechanisms contributing to women\u2019s elevated susceptibility to AD.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13195-022-01106-4","type":"journal-article","created":{"date-parts":[[2022,11,2]],"date-time":"2022-11-02T07:02:35Z","timestamp":1667372555000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Sex differences in Alzheimer\u2019s disease: plasma MMP-9 and markers of disease severity"],"prefix":"10.1186","volume":"14","author":[{"given":"Amaryllis A.","family":"Tsiknia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin E.","family":"Sundermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie T.","family":"Reas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven D.","family":"Edland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James B.","family":"Brewer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas","family":"Galasko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah J.","family":"Banks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the Alzheimer\u2019s Disease Neuroimaging Initiative","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,2]]},"reference":[{"issue":"5","key":"1106_CR1","doi-asserted-by":"publisher","first-page":"651","DOI":"10.3390\/jcm8050651","volume":"8","author":"K Govindpani","year":"2019","unstructured":"Govindpani K, McNamara LG, Smith NR, Vinnakota C, Waldvogel HJ, Faull RL, et al. Vascular dysfunction in Alzheimer\u2019s disease: a prelude to the pathological process or a consequence of it? J Clin Med. 2019;8(5):651.","journal-title":"J Clin Med"},{"issue":"6","key":"1106_CR2","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.4103\/1673-5374.270306","volume":"15","author":"K Govindpani","year":"2020","unstructured":"Govindpani K, Vinnakota C, Waldvogel HJ, Faull RL, Kwakowsky A. Vascular dysfunction in Alzheimer\u2019s disease: a biomarker of disease progression and a potential therapeutic target. Neural Regen Res. 2020;15(6):1030\u20132.","journal-title":"Neural Regen Res"},{"issue":"1","key":"1106_CR3","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/1742-2094-8-26","volume":"8","author":"P Grammas","year":"2011","unstructured":"Grammas P. Neurovascular dysfunction, inflammation and endothelial activation: implications for the pathogenesis of Alzheimer\u2019s disease. J Neuroinflammation. 2011;8(1):26.","journal-title":"J Neuroinflammation"},{"key":"1106_CR4","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.neurobiolaging.2020.06.018","volume":"95","author":"C Ringland","year":"2020","unstructured":"Ringland C, Schweig JE, Paris D, Shackleton B, Lynch CE, Eisenbaum M, et al. Apolipoprotein E isoforms differentially regulate matrix metallopeptidase 9 function in Alzheimer\u2019s disease. Neurobiol Aging. 2020;95:56\u201368.","journal-title":"Neurobiol Aging"},{"key":"1106_CR5","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/B978-0-444-63486-3.00009-8","volume":"214","author":"J Vandooren","year":"2014","unstructured":"Vandooren J, Van Damme J, Opdenakker G. On the structure and functions of gelatinase B\/matrix metalloproteinase-9 in neuroinflammation. Prog Brain Res. 2014;214:193\u2013206.","journal-title":"Prog Brain Res"},{"issue":"34","key":"1106_CR6","doi-asserted-by":"publisher","first-page":"24566","DOI":"10.1074\/jbc.M602440200","volume":"281","author":"P Yan","year":"2006","unstructured":"Yan P, Hu X, Song H, Yin K, Bateman RJ, Cirrito JR, et al. Matrix metalloproteinase-9 degrades amyloid-beta fibrils in vitro and compact plaques in situ. J Biol Chem. 2006;281(34):24566\u201374.","journal-title":"J Biol Chem"},{"issue":"9","key":"1106_CR7","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1177\/0271678X16655551","volume":"36","author":"RG Rempe","year":"2016","unstructured":"Rempe RG, Hartz AM, Bauer B. Matrix metalloproteinases in the brain and blood\u2013brain barrier: versatile breakers and makers. J Cereb Blood Flow Metab. 2016;36(9):1481\u2013507.","journal-title":"J Cereb Blood Flow Metab"},{"issue":"7","key":"1106_CR8","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1038\/35081571","volume":"2","author":"VW Yong","year":"2001","unstructured":"Yong VW, Power C, Forsyth P, Edwards DR. Metalloproteinases in biology and pathology of the nervous system. Nat Rev Neurosci. 2001;2(7):502\u201311.","journal-title":"Nat Rev Neurosci"},{"issue":"2","key":"1106_CR9","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/S1474-4422(09)70016-X","volume":"8","author":"GA Rosenberg","year":"2009","unstructured":"Rosenberg GA. Matrix metalloproteinases and their multiple roles in neurodegenerative diseases. Lancet Neurol. 2009;8(2):205\u201316.","journal-title":"Lancet Neurol"},{"issue":"6","key":"1106_CR10","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1152\/physiol.00029.2013","volume":"28","author":"A Yabluchanskiy","year":"2013","unstructured":"Yabluchanskiy A, Ma Y, Iyer RP, Hall ME, Lindsey ML. Matrix metalloproteinase-9: many shades of function in cardiovascular disease. Physiology. 2013;28(6):391\u2013403.","journal-title":"Physiology."},{"issue":"S2","key":"1106_CR11","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1111\/jnc.13415","volume":"139","author":"B Vafadari","year":"2016","unstructured":"Vafadari B, Salamian A, Kaczmarek L. MMP-9 in translation: from molecule to brain physiology, pathology, and therapy. J Neurochem. 2016;139(S2):91\u2013114.","journal-title":"J Neurochem"},{"issue":"3","key":"1106_CR12","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/S0361-9230(03)00097-2","volume":"61","author":"F Sellebjerg","year":"2003","unstructured":"Sellebjerg F, S\u00f8rensen TL. Chemokines and matrix metalloproteinase-9 in leukocyte recruitment to the central nervous system. Brain Res Bull. 2003;61(3):347\u201355.","journal-title":"Brain Res Bull"},{"issue":"12","key":"1106_CR13","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1097\/NEN.0b013e3181c22569","volume":"68","author":"MA Bruno","year":"2009","unstructured":"Bruno MA, Mufson EJ, Wuu J, Cuello AC. Increased matrix metalloproteinase 9 activity in mild cognitive impairment. J Neuropathol Exp Neurol. 2009;68(12):1309\u201318.","journal-title":"J Neuropathol Exp Neurol"},{"issue":"3","key":"1106_CR14","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/S0197-0186(03)00004-4","volume":"43","author":"S Lorenzl","year":"2003","unstructured":"Lorenzl S, Albers DS, Relkin N, Ngyuen T, Hilgenberg SL, Chirichigno J, et al. Increased plasma levels of matrix metalloproteinase-9 in patients with Alzheimer\u2019s disease. Neurochem Int. 2003;43(3):191\u20136.","journal-title":"Neurochem Int"},{"issue":"1","key":"1106_CR15","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1017\/S1041610207005790","volume":"20","author":"S Lorenzl","year":"2008","unstructured":"Lorenzl S, Buerger K, Hampel H, Beal MF. Profiles of matrix metalloproteinases and their inhibitors in plasma of patients with dementia. Int Psychogeriatr. 2008;20(1):67\u201376.","journal-title":"Int Psychogeriatr"},{"issue":"9","key":"1106_CR16","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1002\/acn3.51155","volume":"7","author":"D Gu","year":"2020","unstructured":"Gu D, Liu F, Meng M, Zhang L, Gordon ML, Wang Y, et al. Elevated matrix metalloproteinase-9 levels in neuronal extracellular vesicles in Alzheimer\u2019s disease. Ann Clin Transl Neurol. 2020;7(9):1681\u201391.","journal-title":"Ann Clin Transl Neurol"},{"issue":"24","key":"1106_CR17","doi-asserted-by":"publisher","first-page":"15078","DOI":"10.1074\/jbc.M114.610931","volume":"290","author":"M Hernandez-Guillamon","year":"2015","unstructured":"Hernandez-Guillamon M, Mawhirt S, Blais S, Montaner J, Neubert TA, Rostagno A, et al. Sequential amyloid-\u03b2 degradation by the matrix metalloproteases MMP-2 and MMP-9. J Biol Chem. 2015;290(24):15078\u201391.","journal-title":"J Biol Chem"},{"key":"1106_CR18","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.nbd.2014.06.021","volume":"70","author":"A Fragkouli","year":"2014","unstructured":"Fragkouli A, Tsilibary EC, Tzinia AK. Neuroprotective role of MMP-9 overexpression in the brain of Alzheimer\u2019s 5xFAD mice. Neurobiol Dis. 2014;70:179\u201389.","journal-title":"Neurobiol Dis"},{"issue":"12","key":"1106_CR19","doi-asserted-by":"publisher","first-page":"8296","DOI":"10.1007\/s12035-019-01672-z","volume":"56","author":"B Shackleton","year":"2019","unstructured":"Shackleton B, Ringland C, Abdullah L, Mullan M, Crawford F, Bachmeier C. Influence of matrix metallopeptidase 9 on beta-amyloid elimination across the blood-brain barrier. Mol Neurobiol. 2019;56(12):8296\u2013305.","journal-title":"Mol Neurobiol"},{"issue":"2","key":"1106_CR20","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.expneurol.2012.07.018","volume":"237","author":"G N\u00fcbling","year":"2012","unstructured":"N\u00fcbling G, Levin J, Bader B, Israel L, B\u00f6tzel K, Lorenzl S, et al. Limited cleavage of tau with matrix-metalloproteinase MMP-9, but not MMP-3, enhances tau oligomer formation. Exp Neurol. 2012;237(2):470\u20136.","journal-title":"Exp Neurol"},{"issue":"2","key":"1106_CR21","doi-asserted-by":"publisher","first-page":"553","DOI":"10.3233\/JAD-200146","volume":"76","author":"M Hernandes-Alejandro","year":"2020","unstructured":"Hernandes-Alejandro M, Monta\u00f1o S, Harrington CR, Wischik CM, Salas-Casas A, Cortes-Reynosa P, et al. Analysis of the relationship between metalloprotease-9 and tau protein in Alzheimer\u2019s disease. J Alzheimers Dis. 2020;76(2):553\u201369.","journal-title":"J Alzheimers Dis"},{"issue":"3","key":"1106_CR22","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/alzrt44","volume":"2","author":"E Stomrud","year":"2010","unstructured":"Stomrud E, Bj\u00f6rkqvist M, Janciauskiene S, Minthon L, Hansson O. Alterations of matrix metalloproteinases in the healthy elderly with increased risk of prodromal Alzheimer\u2019s disease. Alzheimers Res Ther. 2010;2(3):20.","journal-title":"Alzheimers Res Ther"},{"key":"1106_CR23","doi-asserted-by":"publisher","first-page":"116989","DOI":"10.1016\/j.jns.2020.116989","volume":"416","author":"K Abe","year":"2020","unstructured":"Abe K, Chiba Y, Hattori S, Yoshimi A, Asami T, Katsuse O, et al. Influence of plasma matrix metalloproteinase levels on longitudinal changes in Alzheimer\u2019s disease (AD) biomarkers and cognitive function in patients with mild cognitive impairment due to AD registered in the Alzheimer\u2019s Disease Neuroimaging Initiative database. J Neurol Sci. 2020;416:116989.","journal-title":"J Neurol Sci"},{"issue":"4","key":"1106_CR24","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.3233\/JAD-180141","volume":"64","author":"CR Beam","year":"2018","unstructured":"Beam CR, Kaneshiro C, Jang JY, Reynolds CA, Pedersen NL, Gatz M. Differences between women and men in incidence rates of dementia and Alzheimer\u2019s disease. J Alzheimers Dis. 2018;64(4):1077\u201383.","journal-title":"J Alzheimers Dis"},{"issue":"9","key":"1106_CR25","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1080\/13803395.2012.712676","volume":"34","author":"K Irvine","year":"2012","unstructured":"Irvine K, Laws KR, Gale TM, Kondel TK. Greater cognitive deterioration in women than men with Alzheimer\u2019s disease: a meta analysis. J Clin Exp Neuropsychol. 2012;34(9):989\u201398.","journal-title":"J Clin Exp Neuropsychol"},{"issue":"1","key":"1106_CR26","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s11682-016-9523-8","volume":"11","author":"MEI Koran","year":"2017","unstructured":"Koran MEI, Wagener M, Hohman TJ. Sex differences in the association between AD biomarkers and cognitive decline. Brain Imaging Behav. 2017;11(1):205\u201313.","journal-title":"Brain Imaging Behav"},{"issue":"5","key":"1106_CR27","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1001\/jamaneurol.2018.4693","volume":"76","author":"RF Buckley","year":"2019","unstructured":"Buckley RF, Mormino EC, Rabin JS, Hohman TJ, Landau S, Hanseeuw BJ, et al. Sex Differences in the association of global amyloid and regional tau deposition measured by positron emission tomography in clinically normal older adults. JAMA Neurol. 2019;76(5):542\u201351.","journal-title":"JAMA Neurol"},{"key":"1106_CR28","doi-asserted-by":"publisher","first-page":"315","DOI":"10.3389\/fnagi.2019.00315","volume":"11","author":"A Rahman","year":"2019","unstructured":"Rahman A, Jackson H, Hristov H, Isaacson RS, Saif N, Shetty T, et al. Sex and gender driven modifiers of Alzheimer\u2019s: the role for estrogenic control across age, race, medical, and lifestyle risks. Front Aging Neurosci. 2019;11:315 Available from: https:\/\/www.frontiersin.org\/article\/10.3389\/fnagi.2019.00315 [cited 12 May 2022].","journal-title":"Front Aging Neurosci"},{"issue":"7","key":"1106_CR29","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.2310\/JIM.0b013e3182279e4b","volume":"59","author":"H Uzui","year":"2011","unstructured":"Uzui H, Sinha SK, Rajavashisth TB. 17\u03b2-Estradiol inhibits oxidized low-density lipoprotein-induced increase in matrix metalloproteinase-9 expression in human macrophages. J Investig Med. 2011;59(7):1104\u20138.","journal-title":"J Investig Med"},{"issue":"6","key":"1106_CR30","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1523\/JNEUROSCI.21-06-01809.2001","volume":"21","author":"E Vegeto","year":"2001","unstructured":"Vegeto E, Bonincontro C, Pollio G, Sala A, Viappiani S, Nardi F, et al. Estrogen prevents the lipopolysaccharide-induced inflammatory response in microglia. J Neurosci. 2001;21(6):1809\u201318.","journal-title":"J Neurosci"},{"issue":"4","key":"1106_CR31","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1210\/er.2016-1007","volume":"37","author":"A Villa","year":"2016","unstructured":"Villa A, Vegeto E, Poletti A, Maggi A. Estrogens, neuroinflammation, and neurodegeneration. Endocr Rev. 2016;37(4):372\u2013402.","journal-title":"Endocr Rev"},{"issue":"2","key":"1106_CR32","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.atherosclerosis.2005.06.011","volume":"185","author":"P Hu","year":"2006","unstructured":"Hu P, Greendale GA, Palla SL, Reboussin BA, Herrington DM, Barrett-Connor E, et al. The effects of hormone therapy on the markers of inflammation and endothelial function and plasma matrix metalloproteinase-9 level in postmenopausal women: the postmenopausal estrogen progestin intervention (PEPI) trial. Atherosclerosis. 2006;185(2):347\u201352.","journal-title":"Atherosclerosis."},{"issue":"4","key":"1106_CR33","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.mcn.2012.02.005","volume":"49","author":"S Merlo","year":"2012","unstructured":"Merlo S, Sortino MA. Estrogen activates matrix metalloproteinases-2 and -9 to increase beta amyloid degradation. Mol Cell Neurosci. 2012;49(4):423\u20139.","journal-title":"Mol Cell Neurosci"},{"issue":"7\u20138","key":"1106_CR34","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1002\/prca.201400178","volume":"9","author":"DS Spellman","year":"2015","unstructured":"Spellman DS, Wildsmith KR, Honigberg LA, Tuefferd M, Baker D, Raghavan N, et al. Development and evaluation of a multiplexed mass spectrometry based assay for measuring candidate peptide biomarkers in Alzheimer\u2019s Disease Neuroimaging Initiative (ADNI) CSF. Proteomics Clin Appl. 2015;9(7\u20138):715\u201331.","journal-title":"Proteomics Clin Appl"},{"issue":"4","key":"1106_CR35","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1002\/ana.21610","volume":"65","author":"LM Shaw","year":"2009","unstructured":"Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC, et al. Cerebrospinal fluid biomarker signature in Alzheimer\u2019s disease neuroimaging initiative subjects. Ann Neurol. 2009;65(4):403\u201313.","journal-title":"Ann Neurol"},{"issue":"3","key":"1106_CR36","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.jalz.2010.03.013","volume":"6","author":"AJ Saykin","year":"2010","unstructured":"Saykin AJ, Shen L, Foroud TM, Potkin SG, Swaminathan S, Kim S, et al. Alzheimer\u2019s Disease Neuroimaging Initiative biomarkers as quantitative phenotypes: genetics core aims, progress, and plans. Alzheimers Dement. 2010;6(3):265\u201373.","journal-title":"Alzheimers Dement"},{"issue":"5","key":"1106_CR37","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/j.jalz.2014.05.1754","volume":"11","author":"D Bertens","year":"2015","unstructured":"Bertens D, Knol DL, Scheltens P, Visser PJ, Alzheimer\u2019s Disease Neuroimaging Initiative. Temporal evolution of biomarkers and cognitive markers in the asymptomatic, MCI, and dementia stage of Alzheimer\u2019s disease. Alzheimers Dement. 2015;11(5):511\u201322.","journal-title":"Alzheimers Dement"},{"issue":"4","key":"1106_CR38","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1080\/10543401003618819","volume":"20","author":"M Heo","year":"2010","unstructured":"Heo M, Leon AC. Sample sizes required to detect two-way and three-way interactions involving slope differences in mixed-effects linear models. J Biopharm Stat. 2010;20(4):787\u2013802.","journal-title":"J Biopharm Stat"},{"issue":"6","key":"1106_CR39","doi-asserted-by":"publisher","first-page":"508","DOI":"10.3109\/00365513.2015.1057760","volume":"75","author":"P Kusnierova","year":"2015","unstructured":"Kusnierova P, Vsiansky F, Pleva L, Plevova P, Safarcik K, Svagera Z. Reference intervals of plasma matrix metalloproteinases 2, 3, and 9 and serum asymmetric dimethylarginine levels. Scand J Clin Lab Invest. 2015;75(6):508\u201313.","journal-title":"Scand J Clin Lab Invest"},{"issue":"24","key":"1106_CR40","doi-asserted-by":"publisher","first-page":"7910","DOI":"10.1523\/JNEUROSCI.16-24-07910.1996","volume":"16","author":"JR Backstrom","year":"1996","unstructured":"Backstrom JR, Lim GP, Cullen MJ, T\u00f6k\u00e9s ZA. Matrix metalloproteinase-9 (MMP-9) is synthesized in neurons of the human hippocampus and is capable of degrading the amyloid-\u03b2 peptide (1\u201340). J Neurosci. 1996;16(24):7910\u20139.","journal-title":"J Neurosci"},{"issue":"11","key":"1106_CR41","doi-asserted-by":"publisher","first-page":"2587","DOI":"10.1111\/jne.12432","volume":"28","author":"AC Duarte","year":"2016","unstructured":"Duarte AC, Hrynchak MV, Gon\u00e7alves I, Quintela T, Santos CRA. Sex hormone decline and amyloid \u03b2 synthesis, transport and clearance in the brain. J Neuroendocrinol. 2016;28(11):2587 Available from: https:\/\/onlinelibrary.wiley.com\/doi\/abs\/10.1111\/jne.12432 [cited 2022 May 11].","journal-title":"J Neuroendocrinol"},{"issue":"1","key":"1106_CR42","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/S0006-8993(01)03024-4","volume":"919","author":"CJ Pike","year":"2001","unstructured":"Pike CJ. Testosterone attenuates \u03b2-amyloid toxicity in cultured hippocampal neurons. Brain Res. 2001;919(1):160\u20135.","journal-title":"Brain Res"},{"issue":"2","key":"1106_CR43","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.atherosclerosis.2012.05.031","volume":"223","author":"RT Lin","year":"2012","unstructured":"Lin RT, Chen CH, Tsai PC, Ho BL, Hank Juo SH, Lin HF. Sex-specific effect of matrix metalloproteinase-9 functional promoter polymorphism on carotid artery stiffness. Atherosclerosis. 2012;223(2):416\u201320.","journal-title":"Atherosclerosis."},{"issue":"4","key":"1106_CR44","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.3233\/JAD-201382","volume":"80","author":"AL Clark","year":"2021","unstructured":"Clark AL, Weigand AJ, Thomas KR, Solders SK, Delano-Wood L, Bondi MW, et al. Elevated inflammatory markers and arterial stiffening exacerbate tau but not amyloid pathology in older adults with mild cognitive impairment. J Alzheimers Dis. 2021;80(4):1451\u201363.","journal-title":"J Alzheimers Dis"},{"issue":"5","key":"1106_CR45","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1001\/jamaneurol.2014.4477","volume":"72","author":"DA Nation","year":"2015","unstructured":"Nation DA, Edmonds EC, Bangen KJ, Delano-Wood L, Scanlon BK, Han SD, et al. Pulse pressure in relation to tau-mediated neurodegeneration, cerebral amyloidosis, and progression to dementia in very old adults. JAMA Neurol. 2015;72(5):546.","journal-title":"JAMA Neurol"},{"issue":"31","key":"1106_CR46","doi-asserted-by":"publisher","first-page":"9665","DOI":"10.1523\/JNEUROSCI.2234-09.2009","volume":"29","author":"S Wray","year":"2009","unstructured":"Wray S, Noble W. Linking amyloid and tau pathology in Alzheimer\u2019s disease: the role of membrane cholesterol in A\u03b2-mediated tau toxicity. J Neurosci. 2009;29(31):9665\u20137.","journal-title":"J Neurosci"},{"issue":"2","key":"1106_CR47","doi-asserted-by":"publisher","first-page":"423","DOI":"10.3233\/JAD-170991","volume":"63","author":"JK Kueper","year":"2018","unstructured":"Kueper JK, Speechley M, Montero-Odasso M. The Alzheimer\u2019s Disease Assessment Scale\u2013Cognitive Subscale (ADAS-Cog): modifications and responsiveness in pre-dementia populations. A narrative review. J Alzheimers Dis. 2018;63(2):423\u201344.","journal-title":"J Alzheimers Dis"},{"issue":"2","key":"1106_CR48","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.trci.2015.07.001","volume":"1","author":"KA Lin","year":"2015","unstructured":"Lin KA, Choudhury KR, Rathakrishnan BG, Marks DM, Petrella JR, Doraiswamy PM, et al. Marked gender differences in progression of mild cognitive impairment over 8 years. Alzheimers Dement (N Y). 2015;1(2):103\u201310.","journal-title":"Alzheimers Dement (N Y)"},{"issue":"37","key":"1106_CR49","doi-asserted-by":"publisher","first-page":"e8072","DOI":"10.1097\/MD.0000000000008072","volume":"96","author":"R Lo Presti","year":"2017","unstructured":"Lo Presti R, Hopps E, Caimi G. Gelatinases and physical exercise: a systematic review of evidence from human studies. Medicine (Baltimore). 2017;96(37):e8072.","journal-title":"Medicine (Baltimore)"},{"issue":"7399","key":"1106_CR50","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1038\/nature11087","volume":"485","author":"RD Bell","year":"2012","unstructured":"Bell RD, Winkler EA, Singh I, Sagare AP, Deane R, Wu Z, et al. Apolipoprotein E controls cerebrovascular integrity via cyclophilin A. Nature. 2012;485(7399):512\u20136.","journal-title":"Nature."},{"issue":"9","key":"1106_CR51","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1001\/jamaneurol.2013.3841","volume":"70","author":"MR Halliday","year":"2013","unstructured":"Halliday MR, Pomara N, Sagare AP, Mack WJ, Frangione B, Zlokovic BV. Relationship between cyclophilin A levels and matrix metalloproteinase 9 activity in cerebrospinal fluid of cognitively normal apolipoprotein E4 carriers and blood-brain barrier breakdown. JAMA Neurol. 2013;70(9):1198\u2013200.","journal-title":"JAMA Neurol"},{"issue":"4","key":"1106_CR52","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1002\/ana.24135","volume":"75","author":"A Altmann","year":"2014","unstructured":"Altmann A, Tian L, Henderson VW, Greicius MD. Sex modifies the APOE-related risk of developing Alzheimer disease. Ann Neurol. 2014;75(4):563\u201373.","journal-title":"Ann Neurol"},{"issue":"17","key":"1106_CR53","doi-asserted-by":"publisher","first-page":"e2378","DOI":"10.1212\/WNL.0000000000010629","volume":"95","author":"RB Mofrad","year":"2020","unstructured":"Mofrad RB, Tijms BM, Scheltens P, Barkhof F, van der Flier WM, Sikkes SAM, et al. Sex differences in CSF biomarkers vary by Alzheimer disease stage and APOE \u03b54 genotype. Neurology. 2020;95(17):e2378\u201388.","journal-title":"Neurology."},{"key":"1106_CR54","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.jsbmb.2016.03.012","volume":"160","author":"BC Riedel","year":"2016","unstructured":"Riedel BC, Thompson PM, Brinton RD. Age, APOE and sex: triad of risk of Alzheimer\u2019s disease. J Steroid Biochem Mol Biol. 2016;160:134\u201347.","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"12","key":"1106_CR55","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1164\/rccm.200402-193OC","volume":"170","author":"T Tazaki","year":"2004","unstructured":"Tazaki T, Minoguchi K, Yokoe T, Samson KTR, Minoguchi H, Tanaka A, et al. Increased levels and activity of matrix metalloproteinase-9 in obstructive sleep apnea syndrome. Am J Respir Crit Care Med. 2004;170(12):1354\u20139.","journal-title":"Am J Respir Crit Care Med"}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-022-01106-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13195-022-01106-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-022-01106-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,2]],"date-time":"2022-11-02T08:04:17Z","timestamp":1667376257000},"score":1,"resource":{"primary":{"URL":"https:\/\/alzres.biomedcentral.com\/articles\/10.1186\/s13195-022-01106-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,2]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["1106"],"URL":"https:\/\/doi.org\/10.1186\/s13195-022-01106-4","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,2]]},"assertion":[{"value":"9 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Institutional Review Board of each research site participating in the ADNI and all participants provided written consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"160"}}